Kailera Therapeutics, Inc.
NASDAQ:KLRABiotechnology
+$0.51 today
- Market cap
- $1.53B
- Beta
- 0.00
Volume 0.42M
Average 0.80M
KLRA Total Assets
Everything the company owns or controls; equal to total liabilities plus equity.
Kailera Therapeutics, Inc.NASDAQ: KLRA
Total Assets · Q2 FY2026 · quarter ended Jun 2026
Total assets of $1.21B in Q2 FY2026
Q2 FY2026 total assets was $1.21B.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Assets history
USD · from the balance sheet
- Latest · FY2025
- 692.29M USD
- Year-over-year change
- —
| Period | Period end | Total Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 692.29M | — |
Total Assets vs competitors
How KLRA compares with its peers on the latest reported figures
- KLRA's Jun 2026 total assets of $1.21B is the highest of the 10 companies compared; the peer median is $335.63M.
| Company | Period | Latest balance | YoY | 3-year CAGR |
|---|---|---|---|---|
KLRAKailera Therapeutics, Inc. | Jun 2026 | $1.21B | — | — |
| Jun 2026 | $704.45M | -13.6% | +17.1% | |
| Jun 2026 | $521.9M | -37.0% | +61.9% | |
MBXMBX Biosciences, Inc. Common Stock | Sep 2026 | $500.62M | +25.1% | +104.4% |
BIOABioAge Labs, Inc. | Mar 2026 | $397.65M | +15.7% | +118.1% |
| Mar 2026 | $335.63M | +113.4% | +10.6% | |
| Mar 2026 | $268.85M | +82.2% | +12.6% | |
| Mar 2026 | $99.39M | +19.7% | +25.8% | |
| Mar 2026 | $98.81M | +208.5% | +39.3% | |
| Mar 2026 | $46.39M | -15.7% | -23.2% | |
| Peer median (excluding KLRA) | $335.63M | +19.7% | +25.8% | |
Competitors are the stored peer set for KLRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2025 Dec 2025 |
|---|---|
| Cash & Equivalents | 160.27M |
| Short-term Investments | 385.79M |
| Net Receivables | 2.73M |
| Inventory | 0 |
| Other Current Assets | 1.23M |
| Total Current Assets | 557.54M |
| Property, Plant & Equipment (Net) | 12.42M |
| Goodwill | 0 |
| Intangible Assets | 0 |
| Long-term Investments | 106.67M |
| Tax Assets | 0 |
| Other Non-current Assets | 15.67M |
| Total Non-current Assets | 134.76M |
| Total Assets | 692.29M |
| Account Payables | 7.53M |
| Short-term Debt | 0 |
| Tax Payables | 0 |
| Deferred Revenue | 0 |
| Other Current Liabilities | 9.97M |
| Total Current Liabilities | 46.41M |
| Long-term Debt | 0 |
| Deferred Tax Liabilities | 0 |
| Deferred Revenue (Non-current) | 0 |
| Other Non-current Liabilities | 992.63M |
| Total Non-current Liabilities | 1B |
| Total Liabilities | 1.05B |
| Common Stock | 0 |
| Retained Earnings | (368.67M) |
| Accumulated OCI | 229K |
| Other Stockholders Equity | 0 |
| Minority Interest | 0 |
| Total Equity | (356.46M) |
| Total Debt | 10.75M |
| Net Debt | (149.51M) |
Kailera Therapeutics, Inc.
NASDAQ:KLRA
Intrinsic Alpha fair value
Locked
Current Price
$11.79
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.